ArticleMaterials today. Bio2026
ROS-responsive hydrogel delivering liposomal indole-3-propionic acid promotes spinal cord injury repair by enhancing CX3CL1-CX3CR1 mediated neuron-microglia communication.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating neurological disorder characterized by excessive neuroinflammation and limited regenerative capacity. Here, we developed a reactive oxygen species (ROS)-responsive hydrogel for localized delivery of liposomal indole-3-propionic acid (IPA), a gut microbiota-derived metabolite with neuroprotective potential. The hydrogel exhibited favorable injectability, self-healing capability, and ROS-responsive degradation, enabling sustained release and prolonged retention of IPA at the lesion site. In vitro, IPA-loaded liposomes effectively attenuated lipopolysaccharide-induced inflammation and promoted axonal regeneration with favorable biosafety. In the rat SCI model, localized delivery of liposomal IPA significantly improved locomotor recovery, electrophysiological function, and tissue preservation while reducing cavity formation and secondary injury. Moreover, IPA promoted neuronal survival, enhanced axonal integrity, and shifted microglia toward a pro-repair phenotype. Single-nucleus RNA sequencing identified enhanced CX3CL1-CX3CR1 mediated neuron-microglia communication following IPA treatment, accompanied by enrichment of PI3K/AKT signaling pathway in both neurons and microglia. In addition, IPA facilitated microglial migration toward the lesion core, suggesting coordinated modulation of the neuroinflammatory microenvironment after SCI. Collectively, our study identifies a previously unrecognized therapeutic role of IPA in spinal cord repair and presents a ROS-responsive nanoplatform for localized metabolite delivery to regulate neuron-microglia crosstalk and promote functional recovery after SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.